TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26290008

Group type: EXPERIMENTAL
Intervention: Bovine meat cooked at 55°C for 5 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bovine meat cooked at 90°C for 30 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both cooking methods
Number of subjects: 16
Study: 24200404

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 21629021

Group type: EXPERIMENTAL
Intervention: Victims with mental disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Victims without mental disorders
Number of subjects: 0
Study: 19415543

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strontium ranelate; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 16538619

Group type: EXPERIMENTAL
Intervention: 5 mg alendronate + 1,000 IU vitamin D2
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo + 1,000 IU vitamin D2
Number of subjects: 288
Study: 15480128

Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided bilateral facet injections plus supervised stretching exercises (Group A, n = 36)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Supervised stretching exercises alone (Group B, n = 34)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 70
Study: 11336078

Group type: EXPERIMENTAL
Intervention: Pilocarpine 5.0 mg (1 cc) tid at meal times during radiation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9130837

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 97

Group type: COMPARATOR
Intervention: Long-term medication
Number of subjects: 97
Study: 7573830

Group type: EXPERIMENTAL
Intervention: loratadine (20 mg/day orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 2108835

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 25
Study: 11496378

Group type: EXPERIMENTAL
Intervention: Fenbufen
Number of subjects: 71

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 71
Study: 31462143

Group type: EXPERIMENTAL
Intervention: Playing electronic games
Number of subjects: 194
Study: 28796088

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25923680

Group type: EXPERIMENTAL
Intervention: Oxygen-ozone (O2-O3) treatment in addition to conservative treatment with intraforaminal injection of steroid and anaesthetic
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conservative treatment with intraforaminal injection of steroid and anaesthetic
Number of subjects: 154
Study: 23434567

Group type: EXPERIMENTAL
Intervention: Sifalimumab (anti-IFN-α monoclonal antibody)
Number of subjects: 0
Study: 22456295

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg daily for Day 1 - 14
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microgynon® 30 without dalcetrapib
Number of subjects: 30
Study: 20089783

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) - 629 mg/L phenol concentration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO) - 0 mg/L phenol concentration
Number of subjects: 100
Study: 18067035

Group type: EXPERIMENTAL
Intervention: Smoking prevention program
Number of subjects: 2450

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2450
Study: 15853207

Group type: EXPERIMENTAL
Intervention: Drugs other than nitrosourea or drugs that reduce MGMT activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting growth factor receptors such as EGFR or VEGFR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-institutional randomized controlled study by JCOG Brain Tumor Study Group
Number of subjects: 0
Study: 12106730

Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: 911A IOL
Number of subjects: 273

Group type: COMPARATOR
Intervention: Other IOLs (CeeOn Edge 911A, ACR6D, SI‐40NB, Hydroview H60M, Sensar, Stabibag)
Number of subjects: 273
Study: 10387504

Group type: EXPERIMENTAL
Intervention: Experimental group received tailored feedback including psychosocial feedback on attitudes, perceived social support, and self-efficacy expectations.
Number of subjects: 315

Group type: COMPARATOR
Intervention: Comparison group received tailored feedback on fat, fruit, and vegetable consumption without additional psychosocial feedback.
Number of subjects: 315
Study: 8656422

Group type: EXPERIMENTAL
Intervention: Testosterone 2% ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo cream-based preparation
Number of subjects: 32
Study: 1503133

Group type: EXPERIMENTAL
Intervention: Day treatment (experimental condition)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard clinical care (control condition)
Number of subjects: 160
Study: 6697647

Group type: EXPERIMENTAL
Intervention: Activated charcoal (140 gm) in divided doses over 12 hr
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Repeated oral doses of activated charcoal
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 11
Study: 30973596

Group type: EXPERIMENTAL
Intervention: PDR group (n=59)
Number of subjects: 92

Group type: COMPARATOR
Intervention: NPDR group (n=33)
Number of subjects: 92

Group type: COMPARATOR
Intervention: NPDR group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PDR group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Eyes with NVD
Number of subjects: 92
Study: 28508278

Group type: EXPERIMENTAL
Intervention: Physiotherapy programme (active exercises, myofascial release, PNF techniques), 30-min sessions, 3 times a week for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 60
Study: 25909607

Group type: EXPERIMENTAL
Intervention: Galvanophoresis of hydroxide copper-calcium (GP HCC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard irrigation
Number of subjects: 60
Study: 23672413

Group type: EXPERIMENTAL
Intervention: Diastat (feedback module) used for 4 weeks after receiving the smartphone, followed by 8 weeks of using FTA with Diastat.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diastat (feedback module) used for 12 weeks after receiving the smartphone, followed by 8 weeks of using FTA with Diastat.
Number of subjects: 40
Study: 21360075

Group type: EXPERIMENTAL
Intervention: 1.6 ml of 500 μM ICG:HSA
Number of subjects: 18

Group type: COMPARATOR
Intervention: ICG alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 18854201

Group type: EXPERIMENTAL
Intervention: Bolus isoproterenol infusions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17960013

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and fluorouracil (TPF)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil (PF)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 501

Group type: COMPARATOR
Intervention: PF
Number of subjects: 501
Study: 14974959

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional moist gauze therapy
Number of subjects: 54
Study: 11166898

Group type: EXPERIMENTAL
Intervention: Two doses of 90 microg rH5 vaccine
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: One dose of 90 microg rH5 vaccine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 1588830

Group type: EXPERIMENTAL
Intervention: 15 g fructose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 g fructose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 35 g fructose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 g fructose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 8
Study: 3982427

Group type: EXPERIMENTAL
Intervention: Zixoryn (10 mg/ml, 20 mg/kg body weight, single dose)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (untreated neonates)
Number of subjects: 42
Study: 29653390

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily (Group F)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nadroparin 2850 AxaIU (Group H)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 27447940

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No alcohol (control)
Number of subjects: 108
Study: 25302236

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (75 patients)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (75 patients)
Number of subjects: 150
Study: 22114218

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Dysport) (14.3 ± 0.9 U/kg)
Number of subjects: 18
Study: 20800358

Group type: EXPERIMENTAL
Intervention: Fentanyl Pectin Nasal Spray (FPNS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 18723160

Group type: EXPERIMENTAL
Intervention: Prototype awareness enhancing and monitoring device
Number of subjects: 3

Group type: COMPARATOR
Intervention: Observation without the device
Number of subjects: 3
Study: 16650054

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg) as add-on therapy to fluticasone (200 mcg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluticasone (200 mcg) with levocetirizine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12599843

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study: 11236244

Group type: EXPERIMENTAL
Intervention: Hemodialysis (cuprophan membrane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodialysis (polysulphon membrane)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study: 9229320

Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-FU (60 mg/kg)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-FU with Methotrexate (40 mg/m2)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group (High-dose infusional 5-FU without Methotrexate)
Number of subjects: 312
Study: 1635161

Group type: EXPERIMENTAL
Intervention: MAP‐CRC (red cell concentrates stored in MAP solution)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CRC (ordinary red cell concentrates)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MAP‐CRC
Number of subjects: 39
Study: 3513346

Group type: EXPERIMENTAL
Intervention: Imipenem and cilastatin sodium 500 mg every six hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moxalactam 2 grams every eight hours
Number of subjects: 34
Study: 29261010

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (400 mg three times per day for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26892582

Group type: EXPERIMENTAL
Intervention: 100mcg vitamin K2 (MK7 subtype) daily for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23846118

Group type: EXPERIMENTAL
Intervention: Risedronate alone (R group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Risedronate and vitamin K2 (R + K group)
Number of subjects: 101
Study: 22512617

Group type: EXPERIMENTAL
Intervention: Pre-cooling (mixed-methods)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 10
Study: 21726847

Group type: EXPERIMENTAL
Intervention: Pupil-centered ablation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vertex-centered ablation
Number of subjects: 30
Study: 19370271

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Isometric exercise (ISO EX)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mental stressor (exam)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Physical stressors (cold water immersion and isometric exercise)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) correlation
Number of subjects: 79
Study: 16508275

Group type: EXPERIMENTAL
Intervention: Fluoridated salt (250 ppm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-fluoridated salt
Number of subjects: 10
Study: 12725478

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (1.5 mg bolus every 10 minutes)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral morphine (5 mg for opioid-naïve or 10 mg for those on weak opioids, four-hourly)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 62
Study: 10851672

Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lavage
Number of subjects: 62
Study: 9199483

Group type: EXPERIMENTAL
Intervention: Triglyceride lowering diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lipid lowering drug (Gemfibrozil 600 mg b.i.d.)
Number of subjects: 20
Study: 1362821

Group type: EXPERIMENTAL
Intervention: GM‐CSF (granulocyte-macrophage colony-stimulating factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 0
Study: 4059292

Group type: EXPERIMENTAL
Intervention: benserazide/l‐dopa
Number of subjects: 60

Group type: COMPARATOR
Intervention: carbidopa/l‐dopa
Number of subjects: 60
Study: 31981516

Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 30297199

Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Above median fat-loss (ADF)
Number of subjects: 42
Study: 27604670

Group type: EXPERIMENTAL
Intervention: Robotic flexible ureteroscopy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard flexible ureteroscopy
Number of subjects: 132
Study: 24681228

Group type: EXPERIMENTAL
Intervention: 60 μg HB vaccine formulation
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: 30 μg HB vaccine formulation
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: 10 μg HB vaccine formulation
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: All HB vaccine formulations
Number of subjects: 1091
Study: 22400376

Group type: EXPERIMENTAL
Intervention: Risky internet use
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Pathological internet use
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Regular internet use
Number of subjects: 1435
Study: 20175049

Group type: EXPERIMENTAL
Intervention: EndoButton (EB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: RigidFix (RF)
Number of subjects: 67
Study: 18573205

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Non‐reamed intramedullary nailing
Number of subjects: 1200
Study: 16093465

Group type: EXPERIMENTAL
Intervention: Daily parathyroid hormone (1-34) subcutaneously
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cyclic parathyroid hormone (1-34) subcutaneously for three 3-month cycles
Number of subjects: 126

Group type: COMPARATOR
Intervention: Alendronate alone
Number of subjects: 126
Study: 10077715

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Anthroposophical therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Mainstream medicine (control group)
Number of subjects: 500
Study: 7737555

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2390654

Group type: EXPERIMENTAL
Intervention: Coma arousal procedure (vigorous sensory stimulation using Comakits)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no coma arousal procedure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coma arousal procedure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 7214787

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 15
Study: 31128485

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) therapy
Number of subjects: 3483

Group type: COMPARATOR
Intervention: Non-Traditional Chinese Medicine (non-TCM)
Number of subjects: 3483
Study: 27227793

Group type: EXPERIMENTAL
Intervention: Upper-body strength training session after muscle-damaging exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive recovery condition
Number of subjects: 0
Study: 25801871

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2800 IU per day (n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (n=100)
Number of subjects: 200
Study: 23400997

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 56
Study: 21220395

Group type: EXPERIMENTAL
Intervention: Food-insecure girls
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Food-insecure girls in food-insecure households
Number of subjects: 2084
Study: 20030495

Group type: EXPERIMENTAL
Intervention: Trinidad and Tobago family HIV Workshop
Number of subjects: 180

Group type: COMPARATOR
Intervention: General workshop
Number of subjects: 180
Study: 16981314

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK‐506)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15245813

Group type: EXPERIMENTAL
Intervention: Instruments sent from the Department of Urology in Lund (Lund patients)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Instruments sent from a neutral third party (Stockholm patients)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: QLQ‐BLM30 instrument
Number of subjects: 119
Study: 9033441

Group type: EXPERIMENTAL
Intervention: Inhaled broxaterol 400 micrograms t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 24
Study: 8511728

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5% solution by nebuliser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline 0.9% solution by nebuliser
Number of subjects: 40
Study: 2442317

Group type: EXPERIMENTAL
Intervention: cisplatin, vinblastine, and bleomycin (PVB)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide (VP‐16), and bleomycin (PVP16B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No prior radiotherapy or limited‐field (chest or abdomen) radiotherapy
Number of subjects: 62
Study: 29151179

Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with 10 ml of lidocaine 2%, 5 min before ESWL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with 10 ml lidocaine 2% + intramuscular diclofenac sodium 45 min before ESWL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with 10 ml of lidocaine 2% + tramadol at 1 mg/Kg of weight, 45 min before ESWL
Number of subjects: 70
Study: 26837628

Group type: COMPARATOR
Intervention: Vaginal ring containing dapivirine, maraviroc, or both drugs for 28 days
Number of subjects: 48
Study: 24272023

Group type: EXPERIMENTAL
Intervention: Interrupted mattress suture using non-absorbable polypropylene (group I)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Subcuticular suture using non-absorbable polypropylene (group II)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Interrupted mattress suture (group I)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Subcuticular suture (group II)
Number of subjects: 130
Study: 23732051

Group type: EXPERIMENTAL
Intervention: Flucloxacillin 500 mg four times daily and phenoxymethylpenicillin 500 mg four times daily (dual therapy)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Flucloxacillin 500 mg four times daily (monotherapy)
Number of subjects: 172
Study: 20576631

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in 23 patients (Group NOR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ephedrine (max. 10 mg) administered in 21 patients (Group EPH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal volunteers (11 subjects)
Number of subjects: 44
Study: 18378520

Group type: COMPARATOR
Intervention: Ramipril (10 mg per day)
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Telmisartan (80 mg per day)
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Combination therapy (ramipril + telmisartan)
Number of subjects: 25620
Study: 15086766

Group type: EXPERIMENTAL
Intervention: Cohesive short-stretch system (Actico, Activa Healthcare)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Four-layer bandage system
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 156
Study: 11434703

Group type: EXPERIMENTAL
Intervention: Dietary n-3 fatty acids (0.1 g/kg/d as menhaden fish oil containing 12% EPA and 18% DHA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control dietary olive oil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dietary n-3 fatty acids
Number of subjects: 10
Study: 9931626

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio- and/or chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-field lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-field lymphadenectomy
Number of subjects: 0
Study: 8311283

Group type: EXPERIMENTAL
Intervention: 3% gelatin in electrolyte solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Isotonic saline 0.9%
Number of subjects: 34
Study: 2969537

Group type: EXPERIMENTAL
Intervention: Continuous sutures
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 40
Study: 31563386

Group type: EXPERIMENTAL
Intervention: NSAID therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sham taping with NSAID therapy
Number of subjects: 84